Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse

V. Montefusco, A. Corso, M. Galli, I. Ardoino, S. Pezzatti, C. Carniti, F. Patriarca, F. Gherlinzoni, R. Zambello, S. Sammassimo, M. Marcatti, A. Nozza, C. Crippa, A.M. Cafro, L. Baldini, P. Corradini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)907-917
Number of pages11
JournalBritish Journal of Haematology
Volume188
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • bortezomib
  • lenalidomide
  • myeloma
  • CD4 antigen
  • CD56 antigen
  • CD8 antigen
  • cyclophosphamide
  • dexamethasone
  • immunoglobulin A
  • immunoglobulin M
  • adult
  • aged
  • Article
  • blood toxicity
  • bone marrow toxicity
  • cancer combination chemotherapy
  • cancer recurrence
  • CD3+ T lymphocyte
  • CD4+ T lymphocyte
  • CD8+ T lymphocyte
  • comparative study
  • controlled study
  • drug cost
  • drug efficacy
  • drug response
  • drug safety
  • drug withdrawal
  • female
  • human
  • human cell
  • immune reconstitution
  • immunoglobulin blood level
  • immunophenotyping
  • lymphocyte count
  • major clinical study
  • male
  • median survival time
  • multicenter study
  • multiple cycle treatment
  • multiple myeloma
  • neutropenia
  • open study
  • overall survival
  • patient compliance
  • peripheral neuropathy
  • phase 3 clinical trial
  • priority journal
  • progression free survival
  • randomized controlled trial

Cite this